Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Oscillating devices vs PEP Sputum:weight (dry or wet) (g) · adults and children with cystic fibrosis Oscillating devices for airway clearance in people with cystic fibrosis (2020) · Cochrane | no estimate extracted | 4 studies · 104 participants | Low |
Oscillating devices vs PEP Frequency of exacerbationsb · adults and children with cystic fibrosis Oscillating devices for airway clearance in people with cystic fibrosis (2020) · Cochrane | no estimate extracted | 4 studies · 219 participants | Low |
Oscillating devices vs PEP Participant‐reported satisfaction with treatment intervention · adults and children with cystic fibrosis Oscillating devices for airway clearance in people with cystic fibrosis (2020) · Cochrane | no estimate extracted | 7 studies · 242 participants | Very low |
Oscillating devices vs breathing techniques FEV1: % predicted or L · adults and children with cystic fibrosis Oscillating devices for airway clearance in people with cystic fibrosis (2020) · Cochrane | no estimate extracted | 9 studies · 210 participants | Low |
Oscillating devices vs breathing techniques FEF25-75 · adults and children with cystic fibrosis Oscillating devices for airway clearance in people with cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 29 participants | Very low |
Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing) Lung function(FEV1 or FVC L/min or % predicted) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing) Time to next exacerbation · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… (2020) · Cochrane | no estimate extracted | 1 study · 82 participants | Moderate |
Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing) Quality of life · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing) Length of hospital stay · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing) Sputum bacterial density (CFU/mL) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing) Adverse events · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing) Mortality · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: β‐carotene vs placebo Pulmonary exacerbations Days of antibiotic use · children and adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 24 participants | Low |
Summary of findings: garlic supplementation vs placebo Adverse events mild adverse events · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 26 participants | Moderate |
Summary of findings: garlic supplementation vs placebo Need for antibiotics days of antibiotic use · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: garlic supplementation vs placebo QoL · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: garlic supplementation vs placebo Sputum microbiology · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: garlic supplementation vs placebo Inflammatory markers · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: monoclonal antibody KB001‐A vs placebo Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | RR 0.25 [0.03, 2.4] | 2 studies · 196 participants | Low |
Summary of findings: monoclonal antibody KB001‐A vs placebo Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | RR 4.74 [0.28, 79.44] | 2 studies · 196 participants | Very low |
Summary of findings: monoclonal antibody KB001‐A vs placebo Adverse events number of participants experiencing adverse events · children (12 or over) and adults with cystic fibrosis and lung infection Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | RR 1.3 [0.9, 1.87] | 2 studies · 196 participants | Very low |
Summary of findings: monoclonal antibody KB001‐A vs placebo Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | HR 1 [0.69, 1.45] | 1 study · 169 participants | Moderate |
Summary of findings: monoclonal antibody KB001‐A vs placebo QoL change in CFQ‐R score · children (12 or over) and adults with cystic fibrosis and lung infection Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 27 participants | Low |
Summary of findings: β‐carotene vs placebo Respiratory function absolute FEV1 % predicted · children and adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 24 participants | Low |
Summary of findings: monoclonal antibody KB001‐A vs placebo Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 27 participants | Low |
Summary of findings: monoclonal antibody KB001‐A vs placebo Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 196 participants | Very low |
Summary of findings: nitric oxide vs placebo Pulmonary exacerbations · children (12 or over) and young adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: nitric oxide vs placebo Respiratory function mean change in FEV1 % predicted from baseline · children (12 or over) and young adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 12 participants | Low |
Summary of findings: nitric oxide vs placebo Adverse events · children (12 or over) and young adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 30 participants | Very low |
Summary of findings: nitric oxide vs placebo Need for antibiotics · children (12 or over) and young adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: nitric oxide vs placebo QoL · children (12 or over) and young adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: nitric oxide vs placebo Sputum microbiology · children (12 or over) and young adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 30 participants | Very low |
Summary of findings: nitric oxide vs placebo Inflammatory markers · children (12 or over) and young adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Zinc supplementation vs placebo Pulmonary exacerbations number of participants requiring IV antibiotics · children with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | RR 1.85 [0.65, 5.26] | 1 study · 37 participants | Moderate |
Summary of findings: β‐carotene vs placebo Adverse events · children and adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 24 participants | Low |
Summary of findings: Zinc supplementation vs placebo Respiratory function mean FEV1 % predicted · children with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 62 participants | Very low |
Summary of findings: Zinc supplementation vs placebo Adverse events number of participants hospitalised during the trial · children with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | RR 1.23 [0.51, 2.97] | 1 study · 37 participants | Moderate |
Summary of findings: Zinc supplementation vs placebo Need for antibiotics number of days on IV or oral antibiotics · children with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | MD 0.52 | 2 studies · 62 participants | Very low |
Summary of findings: Zinc supplementation vs placebo QoL · children with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Zinc supplementation vs placebo Sputum microbiology · children with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Zinc supplementation vs placebo Inflammatory markers · children with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: β‐carotene vs placebo Need for antibiotics see pulmonary exacerbations · children and adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: β‐carotene vs placebo QoL · children and adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: β‐carotene vs placebo Sputum microbiology · children and adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: β‐carotene vs placebo Inflammatory markers · children and adults with cystic fibrosis Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: garlic supplementation vs placebo Pulmonary exacerbations · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: garlic supplementation vs placebo Respiratory function change from baseline in % predicted FEV1 · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane | MD 1.59 | 1 study · 26 participants | Moderate |
Summary of findings: ECM vs NECT plus cimetidine Change in weight (kg) · adults with cystic fibrosis Pancreatic enzyme replacement therapy for people with cystic fibrosis (2020) · Cochrane | MD 0.4 | 1 study · 12 participants | Very low |
Summary of findings: ECM vs ECT Change in BMI · children and adults with cystic fibrosis Pancreatic enzyme replacement therapy for people with cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ECM vs ECT Frequency of bowel symptoms: abdominal pain (% of days affected) · children and adults with cystic fibrosis Pancreatic enzyme replacement therapy for people with cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 41 participants | Very low |